Dr. Mistry on Gaucher Disease Entering a New Era

Dr. Pramod Mistry from Yale University School of Medicine on Gaucher Disease Entering a New Era

Pramod K. Mistry, MD, PhD, Professor of Pediatrics and Internal Medicine, chief, Department of Pediatric GI/Hepatology, Yale University School of Medicine, explains that Gaucher disease does not only effect macrophage cell types. Related diseases such as cancer, Parkinson, and osteoporosis occur as a direct interaction with cells across the entire body.

Currently approved options are successful at controlling Gaucher disease but do not focus on the entire body. The next step is to have an agent that can actively regulate lipid metabolism in all cells.

The Genzyme Corporation drug eliglustat is currently under investigation and may be able to fulfill the full management of lipid metabolism. After a successful phase II trial the drug is now moving on to a phase III investigation. If approved this drug may prove useful at fulfilling the unmet needs of Gaucher disease.

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD